Business Context and Reporting Period
Cytosorbents Corporation, a Delaware corporation, filed this Form 8-K on April 5, 2017, to report the completion of a previously announced equity offering.
Key Financial Metrics
- Gross Proceeds: Approximately $10,000,000 from the sale of 2,222,222 shares of common stock.
- Offering Price: $4.50 per share.
- Net Proceeds: Approximately $8,900,000 after deducting underwriting discounts, commissions, and estimated expenses.
- Underwriters: Cowen and Company (sole book-running manager); Aegis Capital Corp, H.C. Wainwright & Co., B. Riley & Co., Maxim Group LLC, and Northland Capital Markets (co-managers).
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity positions for the reporting period.
Material Changes
The primary material change is the increase in cash assets resulting from the equity offering. The filing does not provide comparative financial data to quantify changes in operating metrics versus prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors related to the offering beyond the standard disclosure of the transaction completion. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the final net proceeds received after all closing expenses.
- Confirm the updated total share count and dilution impact on existing shareholders.
- Review the Company's intended use of the $8.9 million in net proceeds.
- Check for any lock-up agreements or restrictions on the newly issued shares.